Why the study?
Do olmesartan and PD123319 improve anti-inflammatory and antifibrotic activities in a bleomycin-induced pulmonary fibrosis model?
Do olmesartan and PD123319 improve anti-inflammatory and antifibrotic activities in a bleomycin-induced pulmonary fibrosis model?
Targeting the angiotensin pathway with olmesartan and PD123319 shows promise as an antifibrotic treatment in experimental pulmonary fibrosis.
Supports hypothesis generation for angiotensin-targeted antifibrotics in lung fibrosis; leaves open clinical translation.
BACKGROUND: The angiotensin pathway is involved in the pathogenesis of many fibrotic diseases and in idiopathic pulmonary fibrosis an innate overexpression of angiotensin II, a potent TGF-beta1 inductor has been demonstrated. Angiotensin II therapeutic blockade could be therefore a promising antifibrotic approach. OBJECTIVE: Discussion of the results of a preclinical study assessing the antifibrotic efficacy of olmesartan and PD123319 in an experimental lung fibrosis. METHODS/RESULTS: This study demonstrated that in belomycin-induced pulmonary fibrosis both compounds had significant anti-inflammatory and antifibrotic activities. CONCLUSION: Targeting the angiotensin pathway with specific blocking agents could represent a promising antifibrotic treatment.
No takes yet. Share an insight, caveat, or question.
Sabina A Antoniu (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: